Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry

Mateusz Sokolski; Sander Trenson; Justyna M. Sokolska; Domenico D'Amario; Philippe Meyer; Nana K. Poku; Tor Biering-Sørensen; Mats C. Højbjerg Lassen; Kristoffer G. Skaarup; Eduardo Barge-Caballero; Anne Catherine Pouleur; Davide Stolfo; Gianfranco Sinagra; Klemens Ablasser; Viktoria Muster; Peter P. Rainer; Markus Wallner; Alessandra Chiodini; Pascal S. Heiniger; Fran Mikulicic; Judith Schwaiger; Stephan Winnik; Huseyin A. Cakmak; Margherita Gaudenzi; Massimo Mapelli; Irene Mattavelli; Matthias Paul; Irina Cabac-Pogorevici; Claire Bouleti; Marzia Lilliu; Chiara Minoia; Jeroen Dauw; Jérôme Costa; Ahmet Celik; Nathan Mewton; Carlos E.L. Montenegro; Yuya Matsue; Goran Loncar; Michal Marchel; Aris Bechlioulis; Lampros Michalis; Marcus Dörr; Edgard Prihadi; Felix Schoenrath; Daniel R. Messroghli; Wilfried Mullens; Lars H. Lund; Giuseppe M.C. Rosano; Piotr Ponikowski; Frank Ruschitzka; Andreas J. Flammer

doi:10.1002/ehf2.13549

Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry

Mateusz Sokolski
, Sander Trenson
, Justyna M. Sokolska
, Domenico D'Amario
, Philippe Meyer
, Nana K. Poku
, Tor Biering-Sørensen
, Mats C. Højbjerg Lassen
, Kristoffer G. Skaarup
, Eduardo Barge-Caballero
, Anne Catherine Pouleur
, Davide Stolfo
, Gianfranco Sinagra
, Klemens Ablasser
, Viktoria Muster
, Peter P. Rainer
, Markus Wallner
, Alessandra Chiodini
, Pascal S. Heiniger
, Fran Mikulicic

Judith Schwaiger, Stephan Winnik, Huseyin A. Cakmak, Margherita Gaudenzi, Massimo Mapelli, Irene Mattavelli, Matthias Paul, Irina Cabac-Pogorevici, Claire Bouleti, Marzia Lilliu, Chiara Minoia, Jeroen Dauw, Jérôme Costa, Ahmet Celik, Nathan Mewton, Carlos E.L. Montenegro, Yuya Matsue, Goran Loncar, Michal Marchel, Aris Bechlioulis, Lampros Michalis, Marcus Dörr, Edgard Prihadi, Felix Schoenrath, Daniel R. Messroghli, Wilfried Mullens, Lars H. Lund, Giuseppe M.C. Rosano, Piotr Ponikowski, Frank Ruschitzka, Andreas J. Flammer^*

^*Corresponding author for this work

Department of Cardiology

34 Citations (Scopus)

Abstract

AIMS: We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations.

METHODS AND RESULTS: International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62-81] years, 58% male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44-2.59], P < 0.001). After adjusting, HF remained associated with in-hospital mortality (OR 1.45 [95% confidence interval: 1.01-2.06], P = 0.041). Importantly, 186 of 1282 [15%] patients had an acute HF event during hospitalization (76 [40%] with de novo HF), which was associated with higher in-hospital mortality (89 [48%] vs. 220 [23%]) than in patients without HF event (OR 3.10 [2.24-4.29], P < 0.001).

CONCLUSIONS: Hospitalized COVID-19 patients with HF are at increased risk for in-hospital death. In-hospital worsening of HF or acute HF de novo are common and associated with a further increase in in-hospital mortality.

Original language	English
Journal	ESC Heart Failure
Volume	8
Issue number	6
Pages (from-to)	4955-4967
Number of pages	13
ISSN	2055-5822
DOIs	https://doi.org/10.1002/ehf2.13549
Publication status	Published - Dec 2021

Access to Document

10.1002/ehf2.13549

Cite this

Sokolski, M., Trenson, S., Sokolska, J. M., D'Amario, D., Meyer, P., Poku, N. K., Biering-Sørensen, T., Højbjerg Lassen, M. C., Skaarup, K. G., Barge-Caballero, E., Pouleur, A. C., Stolfo, D., Sinagra, G., Ablasser, K., Muster, V., Rainer, P. P., Wallner, M., Chiodini, A., Heiniger, P. S., ... Flammer, A. J. (2021). Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry. ESC Heart Failure, 8(6), 4955-4967. https://doi.org/10.1002/ehf2.13549

Sokolski, M, Trenson, S, Sokolska, JM, D'Amario, D, Meyer, P, Poku, NK, Biering-Sørensen, T , Højbjerg Lassen, MC , Skaarup, KG, Barge-Caballero, E, Pouleur, AC, Stolfo, D, Sinagra, G, Ablasser, K, Muster, V, Rainer, PP, Wallner, M, Chiodini, A, Heiniger, PS, Mikulicic, F, Schwaiger, J, Winnik, S, Cakmak, HA, Gaudenzi, M, Mapelli, M, Mattavelli, I, Paul, M, Cabac-Pogorevici, I, Bouleti, C, Lilliu, M, Minoia, C, Dauw, J, Costa, J, Celik, A, Mewton, N, Montenegro, CEL, Matsue, Y, Loncar, G, Marchel, M, Bechlioulis, A, Michalis, L, Dörr, M, Prihadi, E, Schoenrath, F, Messroghli, DR, Mullens, W, Lund, LH, Rosano, GMC, Ponikowski, P, Ruschitzka, F & Flammer, AJ 2021, 'Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry', ESC Heart Failure, vol. 8, no. 6, pp. 4955-4967. https://doi.org/10.1002/ehf2.13549

@article{f77f2d85b86042ef881d14bd62fdeacb,

title = "Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry",

abstract = "AIMS: We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations.METHODS AND RESULTS: International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62-81] years, 58\% male), with HF being present in 256 [20\%] patients. Overall in-hospital mortality was 25\% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36\%, n = 92) compared with non-HF patients (23\%, n = 231, odds ratio [OR] 1.93 [95\% confidence interval: 1.44-2.59], P < 0.001). After adjusting, HF remained associated with in-hospital mortality (OR 1.45 [95\% confidence interval: 1.01-2.06], P = 0.041). Importantly, 186 of 1282 [15\%] patients had an acute HF event during hospitalization (76 [40\%] with de novo HF), which was associated with higher in-hospital mortality (89 [48\%] vs. 220 [23\%]) than in patients without HF event (OR 3.10 [2.24-4.29], P < 0.001).CONCLUSIONS: Hospitalized COVID-19 patients with HF are at increased risk for in-hospital death. In-hospital worsening of HF or acute HF de novo are common and associated with a further increase in in-hospital mortality.",

author = "Mateusz Sokolski and Sander Trenson and Sokolska, \{Justyna M.\} and Domenico D'Amario and Philippe Meyer and Poku, \{Nana K.\} and Tor Biering-S{\o}rensen and \{H{\o}jbjerg Lassen\}, \{Mats C.\} and Skaarup, \{Kristoffer G.\} and Eduardo Barge-Caballero and Pouleur, \{Anne Catherine\} and Davide Stolfo and Gianfranco Sinagra and Klemens Ablasser and Viktoria Muster and Rainer, \{Peter P.\} and Markus Wallner and Alessandra Chiodini and Heiniger, \{Pascal S.\} and Fran Mikulicic and Judith Schwaiger and Stephan Winnik and Cakmak, \{Huseyin A.\} and Margherita Gaudenzi and Massimo Mapelli and Irene Mattavelli and Matthias Paul and Irina Cabac-Pogorevici and Claire Bouleti and Marzia Lilliu and Chiara Minoia and Jeroen Dauw and J{\'e}r{\^o}me Costa and Ahmet Celik and Nathan Mewton and Montenegro, \{Carlos E.L.\} and Yuya Matsue and Goran Loncar and Michal Marchel and Aris Bechlioulis and Lampros Michalis and Marcus D{\"o}rr and Edgard Prihadi and Felix Schoenrath and Messroghli, \{Daniel R.\} and Wilfried Mullens and Lund, \{Lars H.\} and Rosano, \{Giuseppe M.C.\} and Piotr Ponikowski and Frank Ruschitzka and Flammer, \{Andreas J.\}",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. ESC Heart Failure published by John Wiley \& Sons Ltd on behalf of European Society of Cardiology.",

year = "2021",

month = dec,

doi = "10.1002/ehf2.13549",

language = "English",

volume = "8",

pages = "4955--4967",

journal = "ESC Heart Failure",

issn = "2055-5822",

publisher = "JohnWiley \& Sons Ltd",

number = "6",

}

TY - JOUR

T1 - Heart failure in COVID-19

T2 - the multicentre, multinational PCHF-COVICAV registry

AU - Sokolski, Mateusz

AU - Trenson, Sander

AU - Sokolska, Justyna M.

AU - D'Amario, Domenico

AU - Meyer, Philippe

AU - Poku, Nana K.

AU - Biering-Sørensen, Tor

AU - Højbjerg Lassen, Mats C.

AU - Skaarup, Kristoffer G.

AU - Barge-Caballero, Eduardo

AU - Pouleur, Anne Catherine

AU - Stolfo, Davide

AU - Sinagra, Gianfranco

AU - Ablasser, Klemens

AU - Muster, Viktoria

AU - Rainer, Peter P.

AU - Wallner, Markus

AU - Chiodini, Alessandra

AU - Heiniger, Pascal S.

AU - Mikulicic, Fran

AU - Schwaiger, Judith

AU - Winnik, Stephan

AU - Cakmak, Huseyin A.

AU - Gaudenzi, Margherita

AU - Mapelli, Massimo

AU - Mattavelli, Irene

AU - Paul, Matthias

AU - Cabac-Pogorevici, Irina

AU - Bouleti, Claire

AU - Lilliu, Marzia

AU - Minoia, Chiara

AU - Dauw, Jeroen

AU - Costa, Jérôme

AU - Celik, Ahmet

AU - Mewton, Nathan

AU - Montenegro, Carlos E.L.

AU - Matsue, Yuya

AU - Loncar, Goran

AU - Marchel, Michal

AU - Bechlioulis, Aris

AU - Michalis, Lampros

AU - Dörr, Marcus

AU - Prihadi, Edgard

AU - Schoenrath, Felix

AU - Messroghli, Daniel R.

AU - Mullens, Wilfried

AU - Lund, Lars H.

AU - Rosano, Giuseppe M.C.

AU - Ponikowski, Piotr

AU - Ruschitzka, Frank

AU - Flammer, Andreas J.

PY - 2021/12

Y1 - 2021/12

N2 - AIMS: We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations.METHODS AND RESULTS: International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62-81] years, 58% male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44-2.59], P < 0.001). After adjusting, HF remained associated with in-hospital mortality (OR 1.45 [95% confidence interval: 1.01-2.06], P = 0.041). Importantly, 186 of 1282 [15%] patients had an acute HF event during hospitalization (76 [40%] with de novo HF), which was associated with higher in-hospital mortality (89 [48%] vs. 220 [23%]) than in patients without HF event (OR 3.10 [2.24-4.29], P < 0.001).CONCLUSIONS: Hospitalized COVID-19 patients with HF are at increased risk for in-hospital death. In-hospital worsening of HF or acute HF de novo are common and associated with a further increase in in-hospital mortality.

AB - AIMS: We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations.METHODS AND RESULTS: International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62-81] years, 58% male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44-2.59], P < 0.001). After adjusting, HF remained associated with in-hospital mortality (OR 1.45 [95% confidence interval: 1.01-2.06], P = 0.041). Importantly, 186 of 1282 [15%] patients had an acute HF event during hospitalization (76 [40%] with de novo HF), which was associated with higher in-hospital mortality (89 [48%] vs. 220 [23%]) than in patients without HF event (OR 3.10 [2.24-4.29], P < 0.001).CONCLUSIONS: Hospitalized COVID-19 patients with HF are at increased risk for in-hospital death. In-hospital worsening of HF or acute HF de novo are common and associated with a further increase in in-hospital mortality.

UR - https://www.scopus.com/pages/publications/85115005047

U2 - 10.1002/ehf2.13549

DO - 10.1002/ehf2.13549

M3 - Journal article

C2 - 34533287

AN - SCOPUS:85115005047

SN - 2055-5822

VL - 8

SP - 4955

EP - 4967

JO - ESC Heart Failure

JF - ESC Heart Failure

IS - 6

ER -

Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry

Abstract

Access to Document

Other files and links

Fingerprint

Cite this